Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
6.22
-0.30 (-4.60%)
At close: Oct 2, 2026, 4:00 PM EDT
6.31
+0.09 (1.45%)
After-hours: Oct 2, 2026, 7:57 PM EDT
Kyverna Therapeutics Market Cap
Kyverna Therapeutics has a market cap or net worth of $384.67 million as of October 2, 2026. Its market cap has increased by 48.99% in one year.
Market Cap
384.67M
Enterprise Value
218.24M
1-Year Change
48.99%
Ranking
Category
Stock Price
$6.22
ChartMarket Cap Chart
Since the IPO on February 8, 2024, Kyverna Therapeutics's market cap has decreased from $898.10M to $384.67M, a decrease of -57.17%. That is a compound annual growth rate of -27.39%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 2, 2026 | 384.67M | -28.37% |
| Dec 31, 2025 | 537.02M | 232.60% |
| Dec 31, 2024 | 161.46M | -82.02% |
| Feb 8, 2024 | 898.10M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Turn Therapeutics | 397.07M |
| Eikon Therapeutics | 397.03M |
| Zura Bio | 393.86M |
| Galectin Therapeutics | 393.31M |
| Relmada Therapeutics | 384.01M |
| Opus Genetics | 381.04M |
| vTv Therapeutics | 379.83M |
| Prelude Therapeutics | 377.99M |